1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Dr Reddy’s Is Pushing For Progress On Multiple Fronts

CEO Sets Out How The Firm Is Remaining Competitive In Generics And Biosimilars

 
• By Dave Wallace

Whether in the competitive world of US generics, the growing global biosimilars arena, or promising new geographical markets, Dr Reddy’s is seeking to capitalize on its strengths to remain competitive while also pushing forward with ESG goals, CEO Erez Israeli tells Generics Bulletin.

Multiple arrows forward
Dr Reddy’s is pushing ahead in multiple business segments • Source: Shutterstock

With Dr Reddy’s global operations comprising a wide range of different activities – each of which falls under one of two “Horizons”, with the first comprising core interests in active pharmaceutical ingredients, generics and biosimilars while the second covers more innovative businesses (see sidebar) – the company is confronting its competitors on a number of different fronts.

However, CEO Erez Israeli tells Generics Bulletin in the second part of an exclusive interview, in each market the Indian giant is looking to capitalize on its strengths through innovation, capacity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.